A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Gatipotuzumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Glycotope
- 02 Jul 2019 This study has been discontinued in UK (End date: 28 Jul 2017) as per European Clinical Trials Database record.
- 31 Aug 2018 Biomarkers information updated
- 24 Oct 2017 This study has been completed in Spain as per Eudra.